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SUPPLEMENTARY FIGURES AND TABLES
Supplementary Figure S1: Expression and phosphorylation levels of indicated proteins prior and after treatment of 
SK-N-AS and IMR32 cells with GI50 or 5xGI50 of GSK461364.
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Supplementary Figure S2: Tumor volume of subcutaneous xenografts of A. SK-N-AS and B. IMR32 cells in nu/nu mice 
treated with GSK461364 (50 mg/kg body weight per day) or control (DMSO). *p<0.05, **p<0.01, ***p<0.001.
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Supplementary Table S2: Downregulated oncogenic gene signatures in SK-N-AS cells after GSK461364 treatment
NAME SIZE NES FDR q-val
E2F3_UP.V1_UP 102 -2.058161 0.0010087
RB_DN.V1_UP 98 -1.865791 0.018181
BMI1_DN.V1_DN 69 -1.734638 0.0694752
HOXA9_DN.V1_DN 126 -1.726351 0.0589909
MTOR_UP.N4.V1_DN 126 -1.725022 0.0484205
RB_P107_DN.V1_UP 105 -1.650996 0.0921446
CSR_EARLY_UP.V1_DN 93 -1.625697 0.1059141
BRCA1_DN.V1_DN 50 -1.607157 0.1112663
TGFB_UP.V1_DN 102 -1.606911 0.0989034
IL21_UP.V1_DN 43 -1.592734 0.1043842
CAHOY_NEURONAL 23 -1.573932 0.1153082
EGFR_UP.V1_DN 129 -1.567725 0.1121954
ESC_V6.5_UP_LATE.V1_UP 96 -1.531083 0.1473696
LTE2_UP.V1_UP 117 -1.513094 0.1616007
BCAT_GDS748_DN 36 -1.509661 0.1558804
CSR_LATE_UP.V1_DN 95 -1.491467 0.1704251
ERB2_UP.V1_UP 90 -1.491092 0.1608847
BMI1_DN_MEL18_DN.V1_DN 63 -1.461348 0.1948672
STK33_NOMO_DN 138 -1.412927 0.2684895
KRAS.300_UP.V1_DN 15 -1.409728 0.2622002
